Background. Programs for the prevention of mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) have been scaled up in many low-and middle-income countries. However, HIV drug resistance (HIVDR) data among HIV-1-infected young children remain limited.
Global coverage of prevention of mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) increased dramatically from 50% in 2010 to 77% in 2015 [1] . With increased coverage, the number of new HIV infections among children aged 0-14 years has declined by 51% since 2010. Despite scale-up of PMTCT interventions, an estimated 150 000 children aged <15 years were newly infected with HIV in 2014 [1] .
While critical to reducing the number of new HIV infections in infants, expansion of nonnucleoside reverse transcriptase inhibitor (NNRTI)-based PMTCT has resulted in an increase in HIV drug resistance (HIVDR) among infants and children who acquire HIV infection [2] . Understanding levels of HIVDR prior to treatment initiation is particularly important in children because, on average, they have higher viral loads (VLs) and faster disease progression compared to adults [3] [4] [5] . The limited number of antiretroviral (ARV) drugs available for children necessitates use of the most potent and effective drugs possible. Moreover, HIVDR at the time of treatment initiation, or pretreatment HIVDR (PDR), in children has been shown to be a strong predictor of treatment failure and death [6] [7] [8] [9] .
History of NNRTI exposure has been used as a marker to identify children who are more likely to have HIVDR and who therefore should initiate lopinavir/ritonavir (LPV/r)-based antiretroviral therapy (ART), instead of a standard first-line NNRTIbased regimen [10] . In 2013, the World Health Organization (WHO) recommended use of LPV/r-based ART as the regimen of choice for HIV-infected children aged <3 years, irrespective of PMTCT exposure history [11] . Nonetheless, in many countries a significant proportion of infants and young children continue to initiate NNRTI-based regimens due to challenges of procuring and administering LPV/r syrup.
A greater understanding of the prevalence of PDR among young children is needed in order to support country and global recommendations regarding optimal regimen choice and potentially accelerate a shift toward non-NNRTI-based regimens in this population and to evaluate potential risks that NNRTI resistance may pose when considering protease inhibitor (PI)-sparing strategies [12] . This consists of changing children from PI-based regimens to NNRTI-based regimens once VL suppression is achieved in order to avoid PI-associated toxicities and adverse events. 
Survey Sampling
Country-specific protocols were developed following WHO's generic 2012 guidance for surveillance of HIVDR in children aged <18 months [13, 14] . The methodology leverages a random sample or census of remnant dried blood spot specimens (DBSS) collected as part of routine early infant diagnosis (EID) testing during a 12-month period. In all countries, all laboratories performing EID contributed DBSS to the sample, with the number of specimens contributed per laboratory proportional to the number of EID specimens tested or proportional to the percentage of HIV-positive infants diagnosed per laboratory in the previous year. In each laboratory, eligible DBSS were sampled using simple random sampling without replacement. The recommended effective sample size, designed to yield a prevalence estimate with a 95% confidence interval (CI) of ±7%, was 245. This sample size was based on the assumption that the true HIVDR prevalence was 50% and the amplification success rate from DBSS was 80% [15] .
Demographic data (age, gender, PMTCT exposure [infant and mother], and breastfeeding status) were abstracted from routine laboratory requisition forms. No participant-level identifying information was recorded. The actual ARVs to which the infant and/or the mother were exposed were not routinely captured during EID testing; thus this information was unavailable for analysis.
Specimens from children receiving ARVs for the treatment of HIV infection (rather than prophylaxis) at the time of specimen collection were excluded.
A nonresearch determination status was granted by the WHO Ethical Review Board, institutional review boards from participating countries, and the associate director for science at the Center for Global Health (CGH), Centers for Disease Control and Prevention (CDC).
Specimen Handling and Genotyping
DBSS were collected, handled, stored, and transported per WHO recommendations [15] . HIVDR testing was performed at 1 of the following 4 laboratories designated by WHO for HIV genotyping from DBSS: the CDC Drug Resistance and Surveillance Laboratory at the Division of Global HIV&TB, CGH, CDC, Atlanta, Georgia; the Institut de Recherche pour le Développement Laboratory, Montpellier, France; the CLS Genotyping Laboratory, Johannesburg General Hospital, South Africa; and the National Institute of Communicable Diseases, Johannesburg, South Africa. Positions 38-240 of the reverse transcriptase region of the HIV-1 pol gene were sequenced using previously described methods [16] [17] [18] [19] . Sequence quality was ensured following WHO guidance [20] .
Data Analyses
HIV-1 subtyping and drug susceptibility prediction were performed using Stanford HIVdb, version 8.3 [21] . For the assessment of HIVDR, scores of low-, intermediate-, or highlevel resistance were combined and designated as "resistant" with respect to 1 or more of the following drugs: nevirapine, efavirenz, or any nucleoside/nucleotide reverse transcriptase inhibitors (NtRTI) [21] . A detailed description of analysis methods is found in the Supplementary Materials.
All analyses were performed using Stata software 14.0 (StataCorp LP, College Station, Texas) [22] .
RESULTS

Survey Population and Antiretroviral Exposure
Overall, 1740 DBSS with unique identification numbers were sampled. A total of 1538 DBSS were genotyped; 88 sequences were excluded (10 with no demographic data, 45 due to poor quality, and 33 from children aged ≥18 months). Amplification failure rates ranged from 6.0% to 17.5%; 1450 sequences were available for HIVDR analysis. As South Africa did not report demographic data, analysis of factors associated with PDR included 1048 sequences with matching clinical data ( Figure 1 ).
Human Immunodeficiency Virus Drug Resistance
Overall, 785 of the 1450 (54.1 %) HIV-infected children had HIVDR to 1 or more ARVs, ranging from 35.0% in Swaziland to 63.9% in Zimbabwe. Predicted levels of NRTI and NNRTI resistance by drug are shown in Figure 2 . Predicted resistance to selected NRTI and NNRTI drugs by country is shown in Supplemental Table 1 . Levels of resistance to EFV or NVP were 53.0% (ranging from 34.0% in Swaziland to 63.9% in Zimbabwe) and to NRTI were 8.8% (ranging from 2.0% to 13.9%); predicted tenofovir resistance was low (<5%). NRTI and NNRTI mutations detected at ≥1% of all sequences analyzed are shown in Figure 3 . Overall, 29.7% and 19.2% of specimens had Y181CFIV and K103NS mutations, respectively. The frequency of mutation at position 181 was higher in Mozambique and Zimbabwe than in the other 3 countries; the proportion of K103NS was higher in South Africa than in other countries. In addition, the frequency of M184IV was higher in South Africa, reaching 9.5%.
The predominant HIV-1 subtype was C (n = 1218; 83.7%), followed by A (n = 146; 10.1%) and D (n = 61; 4.2%). Other subtypes were infrequent (n = 30; 2.1%). A total of 528 children (50.4%) were female; gender data were unavailable for 51 (4.9%). The median age was 4.0 months (interquartile range [IQR], 2.0-8.4 months). Less than half (43.6%) were breastfed; for 42.8% (n = 449) breastfeeding status was unknown. A total of 838 (80.0%) had reported PMTCT exposure: 574 (54.8%) to both maternal and neonatal prophylaxis, 60 (5.7%) to maternal prophylaxis only, 101 (9.6%) to neonatal prophylaxis only, 53 (6.3%) had at least maternal prophylaxis (with unknown neonatal exposure status), and 50 (6.0%) to at least neonatal prophylaxis (with unknown maternal exposure). For 91 (8.7%) maternal and neonatal exposure status was unknown; 119 (11.4 %) children had no reported exposure to any ARV (Table 1) .
Among the 1048 children with genotypic and demographic data, HIVDR was detected in 471 (56.2%) with reported ARV exposure, 28 (23.5%) with no prior ARV exposure, and 30 (33.0%) with unknown exposure. HIVDR levels varied by country (Table 2) .
Risk factors associated with NNRTI resistance were explored in multivariate analysis (Table 3) . Children who had received neonatal prophylaxis independent of maternal prophylaxis were nearly twice as likely to have drug-resistant HIV compared to children who did not receive neonatal prophylaxis, while unknown neonatal exposure did not increase the odds of having an NNRTI-resistant virus. Maternal prophylaxis and unknown maternal ARV exposure were both associated with a higher risk of NNRTI resistance in children. After adjusting for country and exposure to ARVs, increasing age was associated with a decreasing likelihood of HIVDR detection. Prevalence of resistance to NNRTIs decreased with increasing age (61.9% in children aged <3 months to 25.4% in children aged 12-18 months).
When any ARV prophylaxis was considered regardless of whether it had been provided to the mother or to the infant, the risk of NNRTI resistance increased with any exposure (adjusted odds ratio [aOR], 4.36; 95% CI, 2.65,7.15; P < .001). The risk of NNRTI resistance also increased with unknown exposure (aOR, 2.02; 95% CI, 1.04, 3.94; P = .04; Supplementary Table 2) . Breastfeeding status was not associated with NNRTI resistance in countries where breastfeeding information was available (Swaziland, Uganda, and Zimbabwe).
DISCUSSION
The overall prevalence of HIVDR (54.1%) was largely driven by NNRTI resistance, which was present in 53.0% of cases. As expected, the most commonly detected NNRTI resistanceassociated mutations were at positions 103, 106, 181, and 190. In contrast, the prevalence of NRTI resistance (8.9%) was substantially lower and was driven by stavudine (D4T) and lamivudine (3TC)/emtricitabine (FTC) resistance. The K103N and M184V mutations were more frequent in South Africa than in other countries, which could be explained by earlier and/or more prevalent use of EFV and 3TC/FTC in South Africa and possibly by the earlier introduction of option B+ as a PMTCT strategy. The high frequency of mutations at position 181 in Zimbabwe and Mozambique may suggest more frequent use of NVP as a component of PMTCT regimens at the time of the survey. Higher frequency of K65R in South Africa and Zimbabwe may be a result of greater use of tenofovir in the population at the time of the survey.
Detection of NNRTI resistance decreased as children got older, potentially as a result of reversion of NNRTI mutations to wild type or discontinuation of postnatal prophylaxis or breastfeeding. Despite possible reversion to wild type in circulating virus in plasma, proviral DNA-containing mutations that conferred resistance to NNRTI that were present in transmitted viruses are likely to be archived in latently infected cells and may be expressed in the future under NNRTI selective pressure, thus impacting long-term management [23, 24] . As expected, neonatal prophylaxis and maternal ARV exposures were positively associated with selection of NNRTI resistance. Unexpectedly, unknown maternal exposure was significantly associated with NNRTI resistance whereas unknown neonatal exposure was not; this result suggests that the quality of reporting may be better for neonatal prophylaxis than for maternal ARV exposure. Breastfeeding was not associated with HIVDR.
Our findings are consistent with those from a 2016 South African survey among newly diagnosed children in which 56.8% and 14.8% had NNRTI and NRTI resistance, respectively [14] . Findings are also consistent with a study of HIVinfected children diagnosed through Togo's EID program: 64% of children with any PMTCT exposure had NNRTI HIVDR compared to 22% with no exposure and 38% with unknown exposure [21] . Our study extends the observations across 5 countries and demonstrates significant differences between them, which are not fully explained by differences in prevalence of exposure to ARVs through PMTCT. While the highest level of resistance (56.1%) was observed in children with reported exposure to ARVs, 33% and 23.5% of children with unknown and no ARV exposure had HIVDR, respectively, suggesting that history of PMTCT exposure may be underreported. This pattern was observed in all 4 countries with epidemiological data, except for Uganda, where children with "unknown" and "no" exposures had similar estimates of resistance. It is possible that misclassification (ie, children with prior exposure erroneously recorded as unexposed) could have contributed to these findings, highlighting a limitation in use of routine program data.
High levels of NNRTI resistance in children from all categories of ARV exposure support WHO's 2013 recommendation that all children aged <3 years be started on LPV/r-based regimens irrespective of PMTCT exposure. Unfortunately, implementation of this policy has been slow. In a WHO Global ARV use survey conducted in 2016 in 66 low-and middle-income countries (LMIC), which assessed pediatric ARV regimens used in 2015, only 14% of 748 638 children aged 0-15 years received Abbreviation: ARV, antiretroviral; NA, not available. a Prevention of mother-to-child transmission exposure is coded as yes if maternal or neonatal exposure was coded as yes; as no if both maternal and neonatal exposure were coded as no;
and as unknown if maternal and neonatal exposure were coded as unknown. Specimens from South Africa (n = 402) are not included in this analysis as gender, age, breastfeeding, and ARV drug exposures were not collected at the time of the survey.
PI/r-based first-line ART regimens (WHO unpublished data).
Reasons for poor uptake of this policy include lack, until recently, of heat-stable and palatable pediatric formulations of LPV/r, which do not require cold chain until the point of dispensing, and no available fixed-dose combination of LPV/r with a NRTI backbone. These results may be of interest in countries that have adopted LPV/r-based first-line treatment for children aged <3 years and that are interested in simplification strategies that entail substituting LPV/r with NVP or EFV once sustained virological suppression is achieved. The NEVEREST-2 study [25, 26] provided proof of concept for NNRTI-substitution strategies in this population but observed that infants with NNRTI resistance at time of treatment initiation were more likely to fail when switched to NNRTI-based therapy. Our findings suggest that countries with high prevalence of NNRTI resistance in infants starting ART should consider the risks that NNRTI resistance may pose to the success of NNRTI-based ART if a simplification strategy is part of their public health approach. Finally, the levels of observed NNRTI resistance in combination with the challenges associated with widespread implementation of LVP/r in this population should prompt actions to accelerate approval and introduction of integrase inhibitor-based regimens in very young children. While raltegravir is already approved for children aged ≥4 weeks, dolutegravir (DTG) is only approved for children aged >6 years. If approved for use in young children, DTG would have the added value of promoting harmonization with adult regimens, further simplifying the public health approach to first-line ART. Finally, second-generation NNRTIs (etravirine/rilpivirine) are unlikely to be effective treatment options given the observed high rates of HIVDR to these drugs. Moreover, currently neither drug is approved for use in very young children.
WHO-recommended survey methods leverage DBSS and demographic data routinely collected as part of EID in LMIC. While this approach has operational and practical advantages, its results must be interpreted in light of its limitations. Results may not represent all children aged <18 months who are infected with HIV in a country. If EID coverage is low, many children may go undiagnosed, and survey results may not necessarily reflect the total population of children aged <18 months newly infected with HIV. The frequency of EID testing in various sites that contribute specimens may introduce potential bias. If PMTCT sites contribute most diagnostic specimens, children with "no" or "unknown" ARV exposure may be less likely to be tested and therefore not be well represented in the survey. Alternatively, if non-PMTCT sites contribute a majority of EID diagnostic specimens, children exposed to PMTCT may not be well represented. Finally, South Africa did not report demographic information, thus precluding its inclusion when Number of genotyped samples with a resistance mutation (n)/number of genotyped samples (N). c Data on PMTCT exposure history was unavailable from South Africa. testing for associations with PDR. Despite these limitations, as EID in children aged <18 months is a prerequisite to treatment initiation, surveys provide nationally representative data for children who are diagnosed and referred to ART clinics to start therapy.
The high levels of NNRTI resistance observed in this analysis strongly support the use of a non-NNRTI-containing regimen in children as recommended by WHO and reinforce the need to overcome practical barriers to widespread scale-up of PI-based regimens to ensure optimal treatment of HIV-infected children in sub-Saharan Africa. Moreover, results underscore the need to accelerate approval and introduction of integrase inhibitors for use in infants and young children.
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